Short Interest in Mainz Biomed (NASDAQ:MYNZ) Drops By 21.6%

Mainz Biomed (NASDAQ:MYNZ) was the target of a large decrease in short interest in February. As of February 28th, there was short interest totalling 79,700 shares, a decrease of 21.6% from the February 13th total of 101,700 shares. Based on an average daily volume of 208,300 shares, the short-interest ratio is presently 0.4 days. Approximately 3.8% of the company’s stock are short sold.

Mainz Biomed Stock Performance

NASDAQ MYNZ traded down $0.01 on Wednesday, hitting $4.15. The stock had a trading volume of 46,628 shares, compared to its average volume of 90,366. Mainz Biomed has a 52-week low of $3.65 and a 52-week high of $45.20. The company has a market capitalization of $8.30 million, a price-to-earnings ratio of -0.06 and a beta of 0.33. The firm has a 50-day moving average of $5.45 and a 200-day moving average of $7.86.

Institutional Trading of Mainz Biomed

An institutional investor recently bought a new position in Mainz Biomed stock. Virtu Financial LLC acquired a new stake in shares of Mainz Biomed (NASDAQ:MYNZ) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned approximately 0.92% of Mainz Biomed as of its most recent filing with the SEC.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. HC Wainwright downgraded shares of Mainz Biomed from a “buy” rating to a “neutral” rating in a research report on Monday, November 25th. Maxim Group assumed coverage on shares of Mainz Biomed in a research note on Friday, February 14th. They issued a “buy” rating and a $14.00 target price on the stock.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.